ClinicalTrials.gg
CompletedNCT05037929Updated Oct 16, 2026Results posted

A Study to Evaluate the Efficacy and Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease

A Phase 2 interventional study of Astegolimab and Placebo in Chronic Obstructive Pulmonary Disease, sponsored by Genentech, Inc.. Completed at 193 sites in 24 countries. Open to participants aged 40 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 2, Interventional, and Treatment

Updated Oct 16, 2026Results postedStudy documents posted+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
1,334
Allocation
Randomized
Ages
40 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Pulmonary Disease, Chronic Obstructive by Hoffmann-La Roche — 1 open to participants now, 2 under way, 1 of them phase 3. Pulmonary Disease, Chronic Obstructive · Hoffmann-La Roche.

Started
2021
with 1 other
Phase 2
4 of 10
none open now
Registered
4th of 10
by date

Among the 10 studies in Pulmonary Disease, Chronic Obstructive by Hoffmann-La Roche, this one is one of 2 that started in 2021, is one of 4 in phase 2, and was the 4th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

1 of the 10 studies in Pulmonary Disease, Chronic Obstructive by Hoffmann-La Roche is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Pulmonary Disease, Chronic Obstructive by Hoffmann-La Roche, or all of them as a file.
02

Study summary

This study will evaluate the efficacy, safety, and pharmacokinetics of astegolimab in combination with standard of care chronic obstructive pulmonary disease (COPD) maintenance therapy in patients with COPD who are former or current smokers and have a history of frequent exacerbations.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease

Keywords

  • Chronic Obstructive Pulmonary Disease
  • COPD
04

Who can participate

Ages eligible
40 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented physician diagnosis of for at least 12 months
  • History of frequent exacerbations, defined as having had two or more moderate or severe exacerbations occurring within a 12-month period in the 24 months prior to screening
  • Post-bronchodilator >=20 and \<80% of predicted normal value at screening
  • Modified Medical Research Council (dyspnea scale) (mMRC) score >=2
  • Current or former smoker with a minimum of 10 pack-year history
  • History of one of the following combinations of optimized, stable, standard-of-care COPD maintenance therapy for at least 4 weeks prior to screening, with no anticipated changes in therapy prior to initiation of study drug and throughout the study: Inhaled (ICS) plus long-acting beta-agonist (LABA); Long-acting muscarinic antagonist (LAMA) plus LABA; ICS plus LAMA plus LABA

Exclusion criteria

Exclusion Criteria

  • Current documented diagnosis of asthma according to the Global Initiative for Asthma guidelines or other accepted guidelines within 5 years prior to screening
  • History of pulmonary disease other than
  • History of long-term treatment with oxygen at >4.0 liters/minute
  • Lung volume reduction surgery or procedure within 12 months prior to screening
  • Participation in or planned participation in a new pulmonary rehabilitation program. Patients who are in the maintenance phase of a rehabilitation program are eligible
  • History of lung transplant
  • Occurrence of moderate or severe COPD exacerbation, COVID-19, upper or lower respiratory infection, pneumonia, or hospitalization of 24 hours duration within 4 weeks prior to initiation of study drug
  • Treatment with oral, IV, or IM within 4 weeks prior to initiation of study drug
  • Initiation of a methylxanthine preparation, maintenance macrolide therapy, and/or PDE4 inhibitor within 4 weeks prior to screening
  • Unstable cardiac disease, myocardial infarction, or Class III or IV heart failure within 12 months prior to screening
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,334 participants (actual)

Study arms

  • Experimental
    Astegolimab Q2W

    Participants will receive subcutaneous (SC) astegolimab every 2 weeks (Q2W).

    Drug: Astegolimab

  • Experimental
    Astegolimab Q4W

    Participants will receive alternating SC astegolimab and placebo Q2W, thus receiving astegolimab every 4 weeks (Q4W).

    Drug: Astegolimab

  • Placebo comparator
    Placebo

    Participants will receive SC placebo Q2W.

    Drug: Placebo

Interventions

  • Participants will receive SC astegolimab Q2W or Q4W.

  • DrugPlacebo

    Participants will receive SC placebo Q2W.

06

What researchers measure

Primary outcomes

  1. Annualized Rate of Moderate and Severe COPD Exacerbations Over the 52-Week Treatment Period

    A moderate COPD exacerbation was defined as new or increased COPD symptoms (e.g., dyspnea, sputum volume, and sputum purulence) that lead to treatment (duration ≥ 3 days) with systemic corticosteroids (oral, intravenous \[IV\], or intramuscular \[IM\]) at a dose of \> 10 milligrams per day (mg/day) prednisolone equivalent and/or antibiotics. A severe COPD exacerbation was defined as new or increased COPD symptoms that lead to hospitalization (duration \> 24 hours) or death. The unadjusted annual exacerbation rate (AER) was estimated as the total number of moderate and severe COPD exacerbations over the treatment period divided by the total patient-years at risk. The time at risk (in years) was the number of days from the date of first administration of study drug to the date of study completion or discontinuation in the 52-week treatment period, divided by 365.25 days. The adjusted AER was estimated using a negative binomial regression model. Adjusted rate values have been reported.

    Time frame: Baseline up to Week 52

Secondary outcomes

  1. Annualized Rate of Moderate and Severe COPD Exacerbations Over the 52-Week Treatment Period in Participants With Low Baseline Blood Eosinophil Level (< 300 Cells/uL)

    A moderate COPD exacerbation was defined as new or increased COPD symptoms (e.g., dyspnea, sputum volume, and sputum purulence) that lead to treatment (duration ≥ 3 days) with systemic corticosteroids (oral, IV, or IM) at a dose of \>10 mg/day prednisolone equivalent and/or antibiotics. A severe COPD exacerbation was defined as new or increased COPD symptoms that led to hospitalization (duration \> 24 hours) or death. Unadjusted AER was estimated as the total number of moderate and severe COPD exacerbations over the treatment period divided by the total patient-years at risk. The time at risk (in years) was the number of days from the date of first administration of study drug to the date of study completion or discontinuation in the 52-week treatment period, divided by 365.25 days. The adjusted AER was estimated using a negative binomial regression model. Adjusted rate values are reported. Number analyzed is the number of participants with data available for analysis.

    Time frame: Baseline to Week 52

  2. Time to First Moderate or Severe COPD Exacerbation During the 52-Week Treatment Period

    Time to first moderate or severe COPD exacerbation was defined as the time from the first administration of study drug to the first incidence of moderate or severe COPD exacerbation event during the 52-week treatment period. A moderate COPD exacerbation is defined as new or increased COPD symptoms (e.g., dyspnea, sputum volume, and sputum purulence) that lead to treatment (duration ≥ 3 days) with systemic corticosteroids (oral, IV, or IM) at a dose of \> 10 mg/day prednisolone equivalent and/or antibiotics. A severe COPD exacerbation is defined as new or increased COPD symptoms that lead to hospitalization (duration \> 24 hours) or lead to death. Kaplan-Meier (K-M) method was used to estimate the median time.

    Time frame: Baseline up to Week 52

  3. Absolute Change From Baseline in Health-related Quality-of-life (HRQoL) at Week 52, as Assessed Through the St. George's Respiratory Questionnaire-COPD (SGRQ-C) Total Score

    SGRQ-C is a disease-specific, self-administered instrument designed to assess the impact of COPD on participants' health status and well-being based on their perception of COPD-related experiences. The questionnaire consists of 40 items across three sub-domains: symptoms (respiratory symptoms and severity- 7 items), activity (activities causing or limited by breathlessness-13 items) and impacts (social functioning and psychological disturbances due to airway disease- 20 items). Each response is assigned a unique empirically derived weight. Total score is calculated by summing the weights to all the positive responses across each domain, with scores ranging from 0 (no impairment) to 100 (maximum impairment), with lower scores indicating better HRQoL. This analysis used a Mixed Model for Repeated Measurements (MMRM) model. Adjusted mean of change from baseline (CFB) is reported here.

    Time frame: At Week 52

  4. Percentage of Participants With Improvement in HRQoL at Week 52, as Assessed Through SGRQ-C Total Score

    Percentage of participants with SGRQ-C improvement was defined as the percentage of participants with an absolute decrease from baseline of ≥4 points in SGRQ-C total score. SGRQ-C is a disease-specific, self-administered instrument designed to assess the impact of COPD on participants' health status and well-being based on their perception of COPD-related experiences. The questionnaire consists of 40 items across three sub-domains: symptoms (respiratory symptoms and severity- 7 items), activity (activities causing or limited by breathlessness-13 items) and impacts (social functioning and psychological disturbances due to airway disease- 20 items). Each response is assigned a unique empirically derived weight. Total score is calculated by summing the weights to all the positive responses across each domain, with scores ranging from 0 (no impairment) to 100 (maximum impairment), with lower scores indicating better HRQoL.

    Time frame: At Week 52

  5. Absolute Change From Baseline in Post-bronchodilator Forced Expiratory Volume in 1 Second (FEV1) (Liters) at Week 52

    Post-bronchodilator FEV1 was defined as the FEV1 value measured with spirometry 20-30 minutes after bronchodilator use. Maximal bronchodilation was achieved via administration of either albuterol (90 micrograms \[µg\] metered dose) or salbutamol (100 µg metered dose), with or without a spacer device, up to a maximum of 4 inhalations. This analysis used a MMRM model. Adjusted mean of CFB is reported here.

    Time frame: At Week 52

  6. Absolute Change From Baseline in Evaluating Respiratory Symptoms in COPD (E-RS:COPD) Total Score at Week 52

    EXAcerbations of Chronic Pulmonary Disease Tool (EXACT) is a 14-item participant-reported instrument used to assess frequency, severity, \& duration of COPD exacerbations using a daily electronic diary (eDiary). It includes four domains: breathlessness (5 items), cough and sputum (3 items), chest symptoms (3 items), and additional attributes (tired or weak, sleep disturbance, and scared or worried; 3 items). The E-RS:COPD is an 11-item subset of the EXACT designed to assess the severity of cardinal respiratory symptoms of COPD, including breathlessness, cough, sputum, chest congestion, and chest tightness. It consists of three subscales: RS-Breathlessness, RS-Cough \& Sputum, and RS-Chest Symptoms. Items are scored on 5- or 6-point Likert scales, and the total score is calculated by summing the item scores, ranging from 0 (no impact) to 40 (high impact), with higher scores indicating greater symptom severity. This analysis used a MMRM model. Adjusted mean of CFB has been reported here.

    Time frame: At Week 52

  7. Annualized Rate of Severe COPD Exacerbations Over the 52-week Treatment Period

    A severe COPD exacerbation was defined as new or increased COPD symptoms that lead to hospitalization (duration \> 24 hours) or lead to death. The unadjusted annual exacerbation rate (AER) was estimated as the total number of moderate and severe COPD exacerbations over the treatment period divided by the total patient-years at risk. The time at risk (in years) was the number of days from the date of first administration of study drug to the date of study completion or discontinuation in the 52-week treatment period, divided by 365.25 days. The adjusted AER was estimated using a negative binomial regression model. Adjusted rate values have been reported.

    Time frame: Baseline up to Week 52

  8. Absolute Change From Baseline in Five-repetition Sit-to-stand (5STS) Time (Seconds) at Week 52

    The 5STS was used to assess the time taken to stand up from a seated position five times, in as rapid succession as possible. The functional test related strongly to lower limb function and frailty in participants with COPD; an inability to perform a single sit-to-stand or to complete five repeat sit-to-stands within 60 seconds denoted an inability to perform the test. This analysis used a MMRM model. Adjusted mean values have been reported.

    Time frame: At Week 52

  9. Number of Participants With Adverse Events (AEs)

    An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

    Time frame: Up to 98.1 weeks

  10. Main Study: Serum Concentrations of Astegolimab at Specified Timepoints

    PK samples in the main study were collected during the 52-week double-blinded treatment period (Period 1), additional blinded treatment period (Period 2), and SFU period.

    Time frame: Period 1: Pre-dose on Day 1 of Week 1 and at Weeks 4, 12, 24, 36, 52 and 62 (SFU); Period 2: Pre-dose at Weeks 52, 64, 76, 88, and 98 (SFU)

  11. Intensive PK Sampling Substudy: Serum Concentrations of Astegolimab at Specified Timepoints

    PK samples in the intensive PK sampling substudy were collected during the 52-week double-blinded treatment period (Period 1), additional blinded treatment period (Period 2), and SFU period.

    Time frame: Period 1: Pre-dose on Day 1 of Week 1 and at Weeks 4, 12, 24, 36, 48, 52, and 62 (SFU), Post-dose on Days 3, 7, and 10 of Week 1, Day 7 of Week 48, Day 28 post-dose from Week 52; Period 2: Pre-dose at Weeks 52, 64, 76, 88, and 98 (SFU)

  12. Number of Participants With Anti-drug Antibodies (ADAs) to Astegolimab

    Participants were considered to be ADA positive if they were ADA negative at baseline but developed an ADA response following astegolimab administration (treatment-induced ADA response), or if they were ADA positive at baseline and the titer of one or more post-baseline samples was greater than the titer of the baseline sample by a scientifically reasonable margin such as at least 0.60 titer unit (t.u.) greater than the baseline titer result (treatment-enhanced ADA response). Participants with a positive post-baseline sample have been reported here.

    Time frame: Up to 98.1 weeks

07

Results

Posted Oct 16, 2026

Participant flow

A total of 1334 participants with chronic obstructive pulmonary disease (COPD) who were former or current smokers and had a history of frequent exacerbations took part in the study at 191 investigative sites across 24 countries from 05 October 2021 to 07 July 2025.

Participant flow — Overall Study
MilestoneAstegolimab Q2WAstegolimab Q4WPlacebo
Started443447444
Safety-evaluable (se) population449442442
Completed372376375
Not completed717169
Withdrew: Adverse event151113
Withdrew: Death11713
Withdrew: Lack of efficacy341
Withdrew: Lost to follow-up111
Withdrew: Non-compliance with study drug110
Withdrew: Reason not specified211
Withdrew: Physician decision141
Withdrew: Protocol deviation010
Withdrew: Study terminated by sponsor020
Withdrew: Withdrawal by subject373939

Outcome measures

PrimaryAnnualized Rate of Moderate and Severe COPD Exacerbations Over the 52-Week Treatment Period

A moderate COPD exacerbation was defined as new or increased COPD symptoms (e.g., dyspnea, sputum volume, and sputum purulence) that lead to treatment (duration ≥ 3 days) with systemic corticosteroids (oral, intravenous \[IV\], or intramuscular \[IM\]) at a dose of \> 10 milligrams per day (mg/day) prednisolone equivalent and/or antibiotics. A severe COPD exacerbation was defined as new or increased COPD symptoms that lead to hospitalization (duration \> 24 hours) or death. The unadjusted annual exacerbation rate (AER) was estimated as the total number of moderate and severe COPD exacerbations over the treatment period divided by the total patient-years at risk. The time at risk (in years) was the number of days from the date of first administration of study drug to the date of study completion or discontinuation in the 52-week treatment period, divided by 365.25 days. The adjusted AER was estimated using a negative binomial regression model. Adjusted rate values have been reported.

Time frame:
Baseline up to Week 52
Reported as:
Number · exacerbations per patient-year
Annualized Rate of Moderate and Severe COPD Exacerbations Over the 52-Week Treatment Period
exacerbations per patient-yearAstegolimab Q2WAstegolimab Q4WPlacebo
Annualized Rate of Moderate and Severe COPD Exacerbations Over the 52-Week Treatment Period1.1101.2221.315
Statistical analysis
  • Astegolimab Q2W vs Placebo · Negative Binomial Regression Model · p = 0.0468 · Adjusted rate ratio: 0.845 · 95% CI 0.715 to 0.998
  • Astegolimab Q4W vs Placebo · Negative Binomial Regression Model · p = 0.3829 · Adjusted rate ratio: 0.930 · 95% CI 0.789 to 1.095
SecondaryAnnualized Rate of Moderate and Severe COPD Exacerbations Over the 52-Week Treatment Period in Participants With Low Baseline Blood Eosinophil Level (< 300 Cells/uL)

A moderate COPD exacerbation was defined as new or increased COPD symptoms (e.g., dyspnea, sputum volume, and sputum purulence) that lead to treatment (duration ≥ 3 days) with systemic corticosteroids (oral, IV, or IM) at a dose of \>10 mg/day prednisolone equivalent and/or antibiotics. A severe COPD exacerbation was defined as new or increased COPD symptoms that led to hospitalization (duration \> 24 hours) or death. Unadjusted AER was estimated as the total number of moderate and severe COPD exacerbations over the treatment period divided by the total patient-years at risk. The time at risk (in years) was the number of days from the date of first administration of study drug to the date of study completion or discontinuation in the 52-week treatment period, divided by 365.25 days. The adjusted AER was estimated using a negative binomial regression model. Adjusted rate values are reported. Number analyzed is the number of participants with data available for analysis.

Time frame:
Baseline to Week 52
Reported as:
Number · exacerbations per patient-year
Annualized Rate of Moderate and Severe COPD Exacerbations Over the 52-Week Treatment Period in Participants With Low Baseline Blood Eosinophil Level (< 300 Cells/uL)
exacerbations per patient-yearAstegolimab Q2WAstegolimab Q4WPlacebo
Annualized Rate of Moderate and Severe COPD Exacerbations Over the 52-Week Treatment Period in Participants With Low Baseline Blood Eosinophil Level (< 300 Cells/uL)1.1231.2061.295
Statistical analysis
  • Astegolimab Q2W vs Placebo · Negative Binomial Regression · p = 0.1154 · Rate ratio: 0.867 · 95% CI 0.726 to 1.036
  • Astegolimab Q4W vs Placebo · Negative Binomial Regression · p = 0.4206 · Rate ratio: 0.931 · 95% CI 0.782 to 1.108
SecondaryTime to First Moderate or Severe COPD Exacerbation During the 52-Week Treatment Period

Time to first moderate or severe COPD exacerbation was defined as the time from the first administration of study drug to the first incidence of moderate or severe COPD exacerbation event during the 52-week treatment period. A moderate COPD exacerbation is defined as new or increased COPD symptoms (e.g., dyspnea, sputum volume, and sputum purulence) that lead to treatment (duration ≥ 3 days) with systemic corticosteroids (oral, IV, or IM) at a dose of \> 10 mg/day prednisolone equivalent and/or antibiotics. A severe COPD exacerbation is defined as new or increased COPD symptoms that lead to hospitalization (duration \> 24 hours) or lead to death. Kaplan-Meier (K-M) method was used to estimate the median time.

Time frame:
Baseline up to Week 52
Reported as:
Median · weeks
Time to First Moderate or Severe COPD Exacerbation During the 52-Week Treatment Period
weeksAstegolimab Q2WAstegolimab Q4WPlacebo
Time to First Moderate or Severe COPD Exacerbation During the 52-Week Treatment Period42.4 (30.1 to NA)39.9 (31.1 to 46.1)33.7 (27.4 to 44.3)
Statistical analysis
  • Astegolimab Q2W vs Placebo · Log Rank · p = 0.1690 · Hazard ratio (hr): 0.88 · 95% CI 0.74 to 1.06
  • Astegolimab Q4W vs Placebo · Log Rank · p = 0.5662 · Hazard ratio (hr): 0.95 · 95% CI 0.79 to 1.13
SecondaryAbsolute Change From Baseline in Health-related Quality-of-life (HRQoL) at Week 52, as Assessed Through the St. George's Respiratory Questionnaire-COPD (SGRQ-C) Total Score

SGRQ-C is a disease-specific, self-administered instrument designed to assess the impact of COPD on participants' health status and well-being based on their perception of COPD-related experiences. The questionnaire consists of 40 items across three sub-domains: symptoms (respiratory symptoms and severity- 7 items), activity (activities causing or limited by breathlessness-13 items) and impacts (social functioning and psychological disturbances due to airway disease- 20 items). Each response is assigned a unique empirically derived weight. Total score is calculated by summing the weights to all the positive responses across each domain, with scores ranging from 0 (no impairment) to 100 (maximum impairment), with lower scores indicating better HRQoL. This analysis used a Mixed Model for Repeated Measurements (MMRM) model. Adjusted mean of change from baseline (CFB) is reported here.

Time frame:
At Week 52
Reported as:
Mean · score on a scale
Absolute Change From Baseline in Health-related Quality-of-life (HRQoL) at Week 52, as Assessed Through the St. George's Respiratory Questionnaire-COPD (SGRQ-C) Total Score
score on a scaleAstegolimab Q2WAstegolimab Q4WPlacebo
Absolute Change From Baseline in Health-related Quality-of-life (HRQoL) at Week 52, as Assessed Through the St. George's Respiratory Questionnaire-COPD (SGRQ-C) Total Score-6.691 ± 0.767-6.383 ± 0.762-4.888 ± 0.769
Statistical analysis
  • Astegolimab Q2W vs Placebo · MMRM · p = 0.0970 · Difference in adjusted means of cfb: -1.803 · 95% CI -3.934 to 0.327
  • Astegolimab Q4W vs Placebo · MMRM · p = 0.1675 · Difference in adjusted means of cfb: -1.495 · 95% CI -3.619 to 0.629
SecondaryPercentage of Participants With Improvement in HRQoL at Week 52, as Assessed Through SGRQ-C Total Score

Percentage of participants with SGRQ-C improvement was defined as the percentage of participants with an absolute decrease from baseline of ≥4 points in SGRQ-C total score. SGRQ-C is a disease-specific, self-administered instrument designed to assess the impact of COPD on participants' health status and well-being based on their perception of COPD-related experiences. The questionnaire consists of 40 items across three sub-domains: symptoms (respiratory symptoms and severity- 7 items), activity (activities causing or limited by breathlessness-13 items) and impacts (social functioning and psychological disturbances due to airway disease- 20 items). Each response is assigned a unique empirically derived weight. Total score is calculated by summing the weights to all the positive responses across each domain, with scores ranging from 0 (no impairment) to 100 (maximum impairment), with lower scores indicating better HRQoL.

Time frame:
At Week 52
Reported as:
Number · percentage of participants
Percentage of Participants With Improvement in HRQoL at Week 52, as Assessed Through SGRQ-C Total Score
percentage of participantsAstegolimab Q2WAstegolimab Q4WPlacebo
Percentage of Participants With Improvement in HRQoL at Week 52, as Assessed Through SGRQ-C Total Score54.3154.2849.78
Statistical analysis
  • Astegolimab Q2W vs Placebo · Regression, Logistic · p = 0.2126 · Odds ratio (or): 1.20 · 95% CI 0.90 to 1.60
  • Astegolimab Q4W vs Placebo · Regression, Logistic · p = 0.2140 · Odds ratio (or): 1.20 · 95% CI 0.90 to 1.59
SecondaryAbsolute Change From Baseline in Post-bronchodilator Forced Expiratory Volume in 1 Second (FEV1) (Liters) at Week 52

Post-bronchodilator FEV1 was defined as the FEV1 value measured with spirometry 20-30 minutes after bronchodilator use. Maximal bronchodilation was achieved via administration of either albuterol (90 micrograms \[µg\] metered dose) or salbutamol (100 µg metered dose), with or without a spacer device, up to a maximum of 4 inhalations. This analysis used a MMRM model. Adjusted mean of CFB is reported here.

Time frame:
At Week 52
Reported as:
Mean · liters
Absolute Change From Baseline in Post-bronchodilator Forced Expiratory Volume in 1 Second (FEV1) (Liters) at Week 52
litersAstegolimab Q2WAstegolimab Q4WPlacebo
Absolute Change From Baseline in Post-bronchodilator Forced Expiratory Volume in 1 Second (FEV1) (Liters) at Week 52-0.003 ± 0.012-0.001 ± 0.011-0.017 ± 0.012
Statistical analysis
  • Astegolimab Q2W vs Placebo · MMRM · p = 0.3860 · Difference in adjusted means of cfb: 0.014 · 95% CI -0.018 to 0.046
  • Astegolimab Q4W vs Placebo · MMRM · p = 0.3163 · Difference in adjusted means of cfb: 0.016 · 95% CI -0.015 to 0.048
SecondaryAbsolute Change From Baseline in Evaluating Respiratory Symptoms in COPD (E-RS:COPD) Total Score at Week 52

EXAcerbations of Chronic Pulmonary Disease Tool (EXACT) is a 14-item participant-reported instrument used to assess frequency, severity, \& duration of COPD exacerbations using a daily electronic diary (eDiary). It includes four domains: breathlessness (5 items), cough and sputum (3 items), chest symptoms (3 items), and additional attributes (tired or weak, sleep disturbance, and scared or worried; 3 items). The E-RS:COPD is an 11-item subset of the EXACT designed to assess the severity of cardinal respiratory symptoms of COPD, including breathlessness, cough, sputum, chest congestion, and chest tightness. It consists of three subscales: RS-Breathlessness, RS-Cough \& Sputum, and RS-Chest Symptoms. Items are scored on 5- or 6-point Likert scales, and the total score is calculated by summing the item scores, ranging from 0 (no impact) to 40 (high impact), with higher scores indicating greater symptom severity. This analysis used a MMRM model. Adjusted mean of CFB has been reported here.

Time frame:
At Week 52
Reported as:
Mean · score on a scale
Absolute Change From Baseline in Evaluating Respiratory Symptoms in COPD (E-RS:COPD) Total Score at Week 52
score on a scaleAstegolimab Q2WAstegolimab Q4WPlacebo
Absolute Change From Baseline in Evaluating Respiratory Symptoms in COPD (E-RS:COPD) Total Score at Week 52-1.247 ± 0.299-1.318 ± 0.299-1.117 ± 0.298
Statistical analysis
  • Astegolimab Q2W vs Placebo · MMRM · p = 0.7576 · Difference in adjusted means of cfb: -0.130 · 95% CI -0.959 to 0.698
  • Astegolimab Q4W vs Placebo · MMRM · p = 0.6332 · Difference in adjusted means of cfb: -0.202 · 95% CI -1.030 to 0.627
SecondaryAnnualized Rate of Severe COPD Exacerbations Over the 52-week Treatment Period

A severe COPD exacerbation was defined as new or increased COPD symptoms that lead to hospitalization (duration \> 24 hours) or lead to death. The unadjusted annual exacerbation rate (AER) was estimated as the total number of moderate and severe COPD exacerbations over the treatment period divided by the total patient-years at risk. The time at risk (in years) was the number of days from the date of first administration of study drug to the date of study completion or discontinuation in the 52-week treatment period, divided by 365.25 days. The adjusted AER was estimated using a negative binomial regression model. Adjusted rate values have been reported.

Time frame:
Baseline up to Week 52
Reported as:
Number · exacerbations per patient-year
Annualized Rate of Severe COPD Exacerbations Over the 52-week Treatment Period
exacerbations per patient-yearAstegolimab Q2WAstegolimab Q4WPlacebo
Annualized Rate of Severe COPD Exacerbations Over the 52-week Treatment Period0.1820.1980.255
Statistical analysis
  • Astegolimab Q2W vs Placebo · Negative Binomial Regression Model · p = 0.0883 · Adjusted rate ratio: 0.715 · 95% CI 0.486 to 1.052
  • Astegolimab Q4W vs Placebo · Negative Binomial Regression Model · p = 0.1958 · Adjusted rate ratio: 0.778 · 95% CI 0.532 to 1.138
SecondaryAbsolute Change From Baseline in Five-repetition Sit-to-stand (5STS) Time (Seconds) at Week 52

The 5STS was used to assess the time taken to stand up from a seated position five times, in as rapid succession as possible. The functional test related strongly to lower limb function and frailty in participants with COPD; an inability to perform a single sit-to-stand or to complete five repeat sit-to-stands within 60 seconds denoted an inability to perform the test. This analysis used a MMRM model. Adjusted mean values have been reported.

Time frame:
At Week 52
Reported as:
Mean · seconds
Absolute Change From Baseline in Five-repetition Sit-to-stand (5STS) Time (Seconds) at Week 52
secondsAstegolimab Q2WAstegolimab Q4WPlacebo
Absolute Change From Baseline in Five-repetition Sit-to-stand (5STS) Time (Seconds) at Week 52-1.946 ± 0.411-1.669 ± 0.411-1.625 ± 0.413
Statistical analysis
  • Astegolimab Q2W vs Placebo · MMRM · p = 0.5816 · Difference in adjusted means of cfb: -0.321 · 95% CI -1.464 to 0.822
  • Astegolimab Q4W vs Placebo · MMRM · p = 0.9396 · Difference in adjusted means of cfb: -0.044 · 95% CI -1.187 to 1.099
SecondaryNumber of Participants With Adverse Events (AEs)

An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

Time frame:
Up to 98.1 weeks
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs)
ParticipantsAstegolimab Q2WAstegolimab Q4WPlacebo
Number of Participants With Adverse Events (AEs)367370386
SecondaryMain Study: Serum Concentrations of Astegolimab at Specified Timepoints

PK samples in the main study were collected during the 52-week double-blinded treatment period (Period 1), additional blinded treatment period (Period 2), and SFU period.

Time frame:
Period 1: Pre-dose on Day 1 of Week 1 and at Weeks 4, 12, 24, 36, 52 and 62 (SFU); Period 2: Pre-dose at Weeks 52, 64, 76, 88, and 98 (SFU)
Reported as:
Geometric mean · micrograms per milliliter (µg/mL)
Main Study: Serum Concentrations of Astegolimab at Specified Timepoints
micrograms per milliliter (µg/mL)Astegolimab Q2WAstegolimab Q4W
Period 1: Pre-dose on Day 1 of Week 1NA ± NANA ± NA
Period 1: Pre-dose at Week 472.2 ± 69.432.1 ± 73.2
Period 1: Pre-dose at Week 12119 ± 59.954.0 ± 60.8
Period 1: Pre-dose at Week 24124 ± 104.155.8 ± 97.5
Period 1: Pre-dose at Week 36127 ± 118.554.4 ± 110.4
Period 1: At Week 52123 ± 162.649.3 ± 127.4
Period 1: At Week 62 (SFU)12.6 ± 734.83.04 ± 764.2
Period 2: Pre-dose at Week 52107 ± 196.550.4 ± 158.8
Period 2: Pre-dose at Week 64100 ± 170.554.1 ± 182.4
Period 2: Pre-dose at Week 7687.8 ± 416.343.7 ± 333.6
Period 2: Pre-dose at Week 88128 ± 37.485.3 ± 113.0
Period 2: Pre-dose at Week 98 (SFU)8.60 ± 161.825.8 ± 48.3
SecondaryIntensive PK Sampling Substudy: Serum Concentrations of Astegolimab at Specified Timepoints

PK samples in the intensive PK sampling substudy were collected during the 52-week double-blinded treatment period (Period 1), additional blinded treatment period (Period 2), and SFU period.

Time frame:
Period 1: Pre-dose on Day 1 of Week 1 and at Weeks 4, 12, 24, 36, 48, 52, and 62 (SFU), Post-dose on Days 3, 7, and 10 of Week 1, Day 7 of Week 48, Day 28 post-dose from Week 52; Period 2: Pre-dose at Weeks 52, 64, 76, 88, and 98 (SFU)
Reported as:
Geometric mean · µg/mL
Intensive PK Sampling Substudy: Serum Concentrations of Astegolimab at Specified Timepoints
µg/mLAstegolimab Q2WAstegolimab Q4W
Period 1: Pre-dose on Day 1 of Week 1NA ± NANA ± NA
Period 1: Post-dose on Day 3 of Week 140.0 ± 248.840.6 ± 173.5
Period 1: Post-dose on Day 7 of Week 149.8 ± 173.255.2 ± 44.9
Period 1: Post-dose on Day 10 of Week 141.0 ± 229.843.9 ± 152.0
Period 1: Pre-dose at Week 477.9 ± 110.430.7 ± 46.8
Period 1: Pre-dose at Week 12124 ± 126.854.2 ± 60.8
Period 1: Pre-dose at Week 24131 ± 131.862.1 ± 58.7
Period 1: Pre-dose at Week 36120 ± 166.761.5 ± 61.7
Period 1: Pre-dose at Week 48129 ± 174.255.8 ± 62.8
Period 1: Day 7 of Week 48150 ± 151.298.8 ± 46.8
Period 1: Pre-dose at Week 5240.3 ± 3239.454.5 ± 65.9
Period 1: Day 28 Post-dose From Week 522.87 ± NA24.5 ± 120.2
Period 1: Pre-dose at Week 62 (SFU)2.02 ± NA5.32 ± 247.7
Period 2: Pre-dose at Week 52161 ± 39.557.2 ± 59.1
Period 2: Pre-dose at Week 64146 ± 32.659.2 ± 53.3
Period 2: Pre-dose at Week 76147 ± 43.154.3 ± 57.7
Period 2: Pre-dose at Week 88142 ± 43.6103 ± 103.4
Period 2: Pre-dose at Week 98 (SFU)—1.13 ± NA
SecondaryNumber of Participants With Anti-drug Antibodies (ADAs) to Astegolimab

Participants were considered to be ADA positive if they were ADA negative at baseline but developed an ADA response following astegolimab administration (treatment-induced ADA response), or if they were ADA positive at baseline and the titer of one or more post-baseline samples was greater than the titer of the baseline sample by a scientifically reasonable margin such as at least 0.60 titer unit (t.u.) greater than the baseline titer result (treatment-enhanced ADA response). Participants with a positive post-baseline sample have been reported here.

Time frame:
Up to 98.1 weeks
Reported as:
Count of participants · Participants
Number of Participants With Anti-drug Antibodies (ADAs) to Astegolimab
ParticipantsAstegolimab Q2WAstegolimab Q4W
Number of Participants With Anti-drug Antibodies (ADAs) to Astegolimab45

Adverse events

Collected over Up to 98.1 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Astegolimab Q2W13/449 (2.9%)111/449 (24.7%)272/449 (60.6%)
Astegolimab Q4W11/442 (2.5%)126/442 (28.5%)285/442 (64.5%)
Placebo16/442 (3.6%)137/442 (31%)281/442 (63.6%)
Most frequent serious events
Showing 10 of 223
Most frequent serious events
EventAstegolimab Q2WAstegolimab Q4WPlacebo
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders64/44971/44271/442
PneumoniaInfections and infestations15/44911/4429/442
Atrial fibrillationCardiac disorders1/4491/4425/442
COVID-19Infections and infestations2/4494/4425/442
Acute kidney injuryRenal and urinary disorders2/4495/4420/442
Acute respiratory failureRespiratory, thoracic and mediastinal disorders3/4493/4424/442
Respiratory failureRespiratory, thoracic and mediastinal disorders4/4491/4423/442
Cholecystitis acuteHepatobiliary disorders0/4493/4421/442
SepsisInfections and infestations0/4493/4422/442
Rib fractureInjury, poisoning and procedural complications0/4490/4423/442
Most frequent other events
Most frequent other events
EventAstegolimab Q2WAstegolimab Q4WPlacebo
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders226/449238/442237/442
NasopharyngitisInfections and infestations52/44947/44237/442
COVID-19Infections and infestations30/44940/44231/442
Injection site reactionGeneral disorders20/44930/44227/442
Back painMusculoskeletal and connective tissue disorders18/44926/44223/442
HypertensionVascular disorders20/44924/44224/442
Urinary tract infectionInfections and infestations18/44915/44223/442

Baseline characteristics

Intent-to-treat (ITT) population included all randomized participants, whether or not the participant received the assigned treatment, with participants grouped according to the treatment assigned at randomization.

Age, Customized
Age, Customized(Participants)Astegolimab Q2WAstegolimab Q4WPlaceboTotal
Adults (18-64 Years)176151146473
From 65-84 Years261294294849
85 Years and Over62412
Sex: Female, Male
Sex: Female, Male(Participants)Astegolimab Q2WAstegolimab Q4WPlaceboTotal
Female187199202588
Male256248242746
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Astegolimab Q2WAstegolimab Q4WPlaceboTotal
Hispanic or Latino827884244
Not Hispanic or Latino3523613461059
Unknown or Not Reported981431
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Astegolimab Q2WAstegolimab Q4WPlaceboTotal
American Indian or Alaska Native51814
Asian6101026
Native Hawaiian or Other Pacific Islander1214
Black or African American9121536
White4054064001211
More than one race88824
Unknown or Not Reported98219
08

Study locations

193 sites
  • SEC Clinical Research LLC - Dothan 2 - ClinEdge - PPDS
    Dothan, Alabama 36305, United States
  • Jasper Summit Research LLC
    Jasper, Alabama 35501, United States
  • Pulmonary Associates of Mobile PC
    Mobile, Alabama 36608-3135, United States
  • Cadena Care Institute, LLC
    Poway, California 92064-2021, United States
  • Inst. of Healthcare Assessment, Inc.
    San Diego, California 92120, United States
  • Allianz Research Institute Inc
    Westminster, California 92683, United States
  • St. Francis Sleep
    Clearwater, Florida 33765, United States
  • Clinical Site Partners - Leesburg Suite 101 - HyperCore - PPDS
    Leesburg, Florida 34748-5077, United States
  • Pulmonary Specialists of the Palm Beaches
    Loxahatchee Groves, Florida 33470-9206, United States
  • Florida Institute for Clinical Research, LLC
    Orlando, Florida 32825-4454, United States
  • Clinical Site Partners - Winter Park - HyperCore - PPDS
    Winter Park, Florida 32789-4681, United States
  • Northwestern Center for Clinical Research
    Chicago, Illinois 60611, United States
  • Medisphere Medical Research Center, Llc
    Evansville, Indiana 47714, United States
  • Exordia Medical Research, Inc.
    Fall River, Massachusetts 20723, United States
  • Northern Pines Health Center PC
    Buckley, Michigan 49620, United States
  • Revive Research Institute
    Lathrup Village, Michigan 48076, United States
  • Oakland Medical Research
    Troy, Michigan 48085, United States
  • Cardio-Pulmonary Associates
    Chesterfield, Missouri 63017-3627, United States
  • Blessing Health Hannibal
    Hannibal, Missouri 63401, United States
  • Midwest Chest Consultants
    Saint Charles, Missouri 63301, United States
  • CARE Clinical Research
    St Louis, Missouri 63141-6823, United States
  • Midwest Clinical Research LLC
    St Louis, Missouri 63141, United States
  • Sierra Clinical Research - ClinEdge - PPDS
    Las Vegas, Nevada 89106-4159, United States
  • American Health Research Inc.
    Charlotte, North Carolina 28277, United States
  • Clinical Research of Gastonia
    Gastonia, North Carolina 28054-7481, United States
  • Carolina Research Center
    Shelby, North Carolina 28150-3803, United States
  • Southeastern Research Center
    Winston-Salem, North Carolina 27103-4029, United States
  • Temple University Hospital
    Philadelphia, Pennsylvania 19140, United States
  • Lowcountry Lung and Critical Care
    North Charleston, South Carolina 29406, United States
  • Clinical Research of Rock Hill
    Rock Hill, South Carolina 29732-1160, United States
  • Velocity Clinical Research Spartanburg PPDS
    Spartanburg, South Carolina 29303-4225, United States
  • South Texas Medical Research Institute, Inc., dba TTS Research ? ClinEdge ? PPDS
    Boerne, Texas 78006-1993, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
  • Metroplex Pulmonology & Sleep Center
    McKinney, Texas 75069, United States
  • Sherman Clinical Research - ClinEdge - PPDS
    Sherman, Texas 75092, United States
  • University of Virginia Health System
    Charlottesville, Virginia 22903-2980, United States
  • Centro Medico IPAM
    Rosario, Santa Fe Province S2001SBK, Argentina
  • Centro de Investigaciones Clínicas Belgrano
    Buenos Aires, 7240, Argentina
  • Instituto de Investigaciones Clinicas-Mar del Plata
    Buenos Aires, B7600FZN, Argentina
  • Fundacion Cidea
    Buenos Aires, C1121ABE, Argentina
  • Centro Médico Dra de Salvo
    Buenos Aires, C1426ABP, Argentina
  • CARE - Centro de Alergia y Enfermedades Respiratorias
    CABA, C1414AIF, Argentina
  • Instituto de Medicina Respiratoria, IMeR
    Córdoba, X5003DCE, Argentina
  • Centro de Especialidades Medicas Lobos
    Lobos, B7240AAN, Argentina
  • Centro de Investigaciones Medicas Mar Del Plata
    Mar del Plata, 7600, Argentina
  • Instituto Ave Pulmo
    Mar del Plata, B7602DCK, Argentina
  • Fundacion Scherbovsky
    Mendoza, 5500, Argentina
  • INSARES
    Mendoza, M5500CCG, Argentina
  • Centro Respiratorio Quilmes
    Quilmes, B1878FNR, Argentina
  • Instituto Medico Fundacion Grupo Colaborativo Rosario Investigacion y Prevencion Medica
    Rosario, S2013OJN, Argentina
  • Centro Médico Respire
    San Fernando, B1646EBJ, Argentina
  • Instituto De Enfermedades Respiratorias E Investigacion Medica
    San Juan Bautista, CP 1888, Argentina
  • Investigaciones en Patologias Respiratorias
    San Miguel de Tucumán, 4000, Argentina
  • Centro Integral de Medicina Respiratoria (CIMER)
    San Miguel de Tucumán, T4000CBC, Argentina
  • Westmead Hospital
    Westmead, New South Wales 2145, Australia
  • Flinders Medical Centre
    Bedford Park, South Australia 5042, Australia
  • Box Hill Hospital
    Box Hill, Victoria 3128, Australia
  • TrialsWest Pty Ltd
    Spearwood, Western Australia 6163, Australia
  • AZ Sint-Maarten
    Mechelen, Antwerpen 2800, Belgium
  • UZ Antwerpen
    Edegem, 2650, Belgium
  • Private Practice Dr Jean Benoit Martinot
    Erpent, 5101, Belgium
  • UZ Leuven Gasthuisberg
    Leuven, 3000, Belgium
  • AZ Delta
    Roeselare, 8800, Belgium
  • Office of Marc De Meulemeester
    Thuin, 6534, Belgium
  • CHU UCl Namur asbl - Site Godinne
    Yvoir, 5530, Belgium
  • Medical Centre "Asklepii", OOD
    Dupnitsa, 2600, Bulgaria
  • Specialized Hospital for Active Treatment of Pneumophthisiatric Diseases - Haskovo EOOD
    Haskovo, 6300, Bulgaria
  • Medical center Vip Clinic OOD
    Lovech, 5500, Bulgaria
  • Specialized Hospital for Active Treatment of Pneumophthisiatric Diseases-Dr.Nikola Penchev-Paza
    Pazardzhik, 4400, Bulgaria
  • Specialized Hospital for Active Treatment of Pulmonary Diseases- Pernik EOOD
    Pernik, 2300, Bulgaria
  • Medical center Medconsult Pleven OOD
    Pleven, 5800, Bulgaria
  • University Multiprofile Hospital for Active Treatment Sveti Georgi EAD
    Plovdiv, 4001, Bulgaria
  • Medical center Unimed EOOD
    Plovdiv, 4023, Bulgaria
  • Medical Centre Respiro OOD
    Razgrad, 7200, Bulgaria
  • Medical Center Hera EOOD
    Sofia, 1510, Bulgaria
  • University Multiprofile Hospital for Active Treatment and Emergency Medicine N. I. Pirogov EAD
    Sofia, 1606, Bulgaria
  • Medical Center New rehabilitation center EOOD
    Stara Zagora, 6003, Bulgaria
  • Specialized Hospital for Active Treatment of Pneumophthisiatric Diseases-Vratsa
    Vratsa, 3000, Bulgaria
  • Burlington Lung Clinic
    Burlington, Ontario L7N 3V2, Canada
  • St. Joseph's Healthcare Hamilton- Charlton Campus
    Hamilton, Ontario L8N 4A6, Canada
  • Bluewater Clinical Research Group
    Sarnia, Ontario N7T 4X3, Canada
  • Clinique de pneumologie et du sommeil de Lanaudiere
    Saint-Charles-Borromée, Quebec J6E 2B4, Canada
  • University of Saskatchewan, Royal University Hospital
    Saskatoon, Saskatchewan S7N 0W8, Canada
  • Centro de Investigaciones Medicas Respiratorias
    Providencia, Región-MetropolitanadeSantiago 7500000, Chile
  • Centro de Investigación Curico
    Curicó, 3340000, Chile
  • MIRES/MYF estudios clinicos
    Ñuñoa, 7750495, Chile
  • Sociedad Médica SyG SpA
    Providencia, 7500000, Chile
  • Enroll SpA - PPDS
    Providencia, 7500587, Chile
  • Meditek Ltda
    Santiago, 8320000, Chile
  • Centro de Investigacion del Maule
    Talca, Chile
  • Hospital Carlos Van Buren
    Valparaíso, 2340000, Chile
  • MediTrial s.r.o.
    Jind?ich?v Hradec, 377 01, Czechia
  • Plicni Ambulance Kralupy nad Vltavou
    Kralupy nad Vltavou, 278 01, Czechia
  • MUDr. Ilona Pavlisova s.r.o.
    Miroslav, 671 72, Czechia
  • Pneumologie Varnsdorf S.r.o.
    Nový Bor, 473 01, Czechia
  • KASMED s.r.o.
    Tábor, 390 02, Czechia
  • Aalborg Universitetshospital
    Aalborg, 9000, Denmark
  • Gentofte Hospital
    Hellerup, 2900, Denmark
  • Hvidovre Hospital
    Hvidovre, DK-2650, Denmark
  • Odense Universitetshospital
    Odense, 5000, Denmark

Showing the first 100 of 193 sites across 24 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Papi A, Greening NJ, Bhatt SP, Roche N, Celli B, Wedzicha JA, Agusti A, Tal-Singer R, Han MK, Janssens W, Hanania NA, Nair P, Bremner P, Porpodis K, Shibata Y, Korn S, Yang T, Gordon O, Saenz R, Ng J, Cheung DS, Devine J, Grimbaldeston MA, Zhang W, Yang X, Mohan D, Vogelmeier CF, Brightling CE; ALIENTO and ARNASA investigators. Safety and efficacy of astegolimab for COPD with frequent exacerbations regardless of baseline blood eosinophil counts (ALIENTO and ARNASA): randomised, double-blind, placebo-controlled, phase 2b and 3 trials. Lancet. 2026 May 23;407(10543):2027-2039. doi: 10.1016/S0140-6736(26)00637-9. Epub 2026 May 18. PubMed 42150581 ↗
  • Wedzicha JA, Agusti A, Brightling CE, Calverley P, Chalmers JD, Greening NJ, Han MK, Mohan D, Ng J, Papi A, Roche N, Saenz R, Samara K, Tal-Singer R, Vogelmeier CF, Yang X, Celli BR. Astegolimab for COPD With Frequent Exacerbations: Pooled Analysis of the ALIENTO and ARNASA Trials. Am J Respir Crit Care Med. 2026 May 18:aamag226. doi: 10.1093/ajrccm/aamag226. Online ahead of print. PubMed 42148875 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2021 to primary completion in Feb 2025, 40 months.

Results were first posted in Oct 2026, 1 year 7 months after primary completion. A results delay was requested in Feb 2026.

Of 118 industry-sponsored phase 2 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 20. This study's 40 months is above that.

Counting every sponsor, half of 165 studies reached it within 17 months; a quarter within 10 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2021
First posted
Sep 8, 2021
StartActual
Oct 5, 2021
Primary completionActual
Feb 24, 2025
CompletionActual
Jul 7, 2025
Results delay requested
Feb 23, 2026
Results first posted
Oct 16, 2026
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 16, 2026
Sites
19 sites added, 7 sites removed
Show 19 added (4 United States, 4 Poland, 2 Netherlands, 1 Argentina, 1 Belgium, 1 Bulgaria, 1 Canada, 1 France, 1 Germany, 1 Israel, 1 New Zealand, 1 South Korea)
  • St. Francis Sleep · Clearwater, United States
  • Pulmonary Specialists of the Palm Beaches · Loxahatchee Groves, United States
  • Oakland Medical Research · Troy, United States
  • University of Virginia Health System · Charlottesville, United States
  • Fundacion Scherbovsky · Mendoza, Argentina
  • UZ Leuven Gasthuisberg · Leuven, Belgium
  • Medical center Vip Clinic OOD · Lovech, Bulgaria
  • Clinique de pneumologie et du sommeil de Lanaudiere · Saint-Charles-Borromée, Canada
  • Hopital Saint Joseph - Marseille · Marseille, France
  • IKF Pneumologie Mainz · Mainz, Germany
  • Rabin Medical Center · Petach Tiqwa, Israel
  • Catharina Hospital · Eindhoven, Netherlands
  • Dijklander Ziekenhuis - loc Hoorn · Hoorn, Netherlands
  • NZ Respiratory & Sleep Institute · Auckland, New Zealand
  • Specjalistyczny Osrodek Alergologiczno-Internistyczny ALL-MED · Krakow, Poland
  • Ewa Pisarczyk-Bogacka Specjalistyczna Praktyka Lekarska · Wroclaw, Poland
  • ETG Lodz · Lódz, Poland
  • Centrum Medyczne Bydgoszcz- PRATIA - PPDS · Bydgoszcz, Poland
  • Jeonbuk National University Hospital · Jeonju, South Korea
Show 7 removed
  • National Jewish Health · Denver, United States
  • Spartanburg Medical Center · Spartanburg, United States
  • Centrum Medyczne ALL-MED · Krakow, Poland
  • ETG Lodz · Lódz, Poland
  • ETG Siedlce · Siedlce, Poland
  • Dobrostan Gabinety Lekarskie · Wroclaw, Poland
  • Chonbuk National University Hospital · Jeonju, South Korea
Oct 16, 2026
Primary outcomes
1 description edited
What changed in the outcomes
  • DescriptionAnnualized Rate of Moderate and Severe COPD Exacerbations Over the 52-Week Treatment Period: how it is measured was reworded
Oct 16, 2026
Documents
Secondary outcomes
5 edited, 6 added, 1 removed, 1 description edited
What changed in the outcomes
  • EditedAbsolute Change fromFrom Baseline in Health-Relatedrelated Quality -of Life-life (HRQoL) at Week 52, as Assessed Through the St. George's Respiratory Questionnaire-COPD (SGRQ-C) Total ScoreTime frame: Baseline to Week 52 → At Week 52
  • EditedAbsolute Change fromFrom Baseline in Post-Bronchodilatorbronchodilator Forced Expiratory Volume in 1 Second (FEV1) (litersLiters) at Week 52Time frame: Baseline to Week 52 → At Week 52
  • EditedAbsolute Change fromFrom Baseline in Evaluating Respiratory Symptoms in COPD (E-RS:COPD) Total Score at Week 52Time frame: Baseline to Week 52 → At Week 52
  • EditedAnnualized Rate of Moderate and Severe COPD Exacerbations Over the 52-Week Treatment Period in Participants With Low Baseline Blood Eosinophil Level (< 300 Cells/uL)Time frame: Baseline up to Week 52 → Baseline to Week 52
  • EditedAbsolute Change fromFrom Baseline in Five-Repetitionrepetition Sit-to-Standstand (5STS) timeTime (secondsSeconds) at Week 52Time frame: Baseline to Week 52 → At Week 52
  • AddedPercentage of Participants With Improvement in HRQoL at Week 52, as Assessed Through SGRQ-C Total ScoreTime frame: At Week 52
  • AddedAnnualized Rate of Severe COPD Exacerbations Over the 52-week Treatment PeriodTime frame: Baseline up to Week 52
  • AddedNumber of Participants With Adverse Events (AEs)Time frame: Up to 98.1 weeks
  • AddedMain Study: Serum Concentrations of Astegolimab at Specified TimepointsTime frame: Period 1: Pre-dose on Day 1 of Week 1 and at Weeks 4, 12, 24, 36, 52 and 62 (SFU); Period 2: Pre-dose at Weeks 52, 64, 76, 88, and 98 (SFU)
  • AddedIntensive PK Sampling Substudy: Serum Concentrations of Astegolimab at Specified TimepointsTime frame: Period 1: Pre-dose on Day 1 of Week 1 and at Weeks 4, 12, 24, 36, 48, 52, and 62 (SFU), Post-dose on Days 3, 7, and 10 of Week 1, Day 7 of Week 48, Day 28 post-dose from Week 52; Period 2: Pre-dose at Weeks 52, 64, 76, 88, and 98 (SFU)
  • AddedNumber of Participants With Anti-drug Antibodies (ADAs) to AstegolimabTime frame: Up to 98.1 weeks
  • RemovedProportion of SGRQ-C Responders at Week 52Time frame: Baseline to Week 52
  • DescriptionTime to First Moderate or Severe COPD Exacerbation During the 52-Week Treatment Period: how it is measured was reworded
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Results posted
    19 sites added, 7 sites removed
    Show 19 added (4 United States, 4 Poland, 2 Netherlands, 1 Argentina, 1 Belgium, 1 Bulgaria, 1 Canada, 1 France, 1 Germany, 1 Israel, 1 New Zealand, 1 South Korea)
    • St. Francis Sleep · Clearwater, United States
    • Pulmonary Specialists of the Palm Beaches · Loxahatchee Groves, United States
    • Oakland Medical Research · Troy, United States
    • University of Virginia Health System · Charlottesville, United States
    • Fundacion Scherbovsky · Mendoza, Argentina
    • UZ Leuven Gasthuisberg · Leuven, Belgium
    • Medical center Vip Clinic OOD · Lovech, Bulgaria
    • Clinique de pneumologie et du sommeil de Lanaudiere · Saint-Charles-Borromée, Canada
    • Hopital Saint Joseph - Marseille · Marseille, France
    • IKF Pneumologie Mainz · Mainz, Germany
    • Rabin Medical Center · Petach Tiqwa, Israel
    • Catharina Hospital · Eindhoven, Netherlands
    • Dijklander Ziekenhuis - loc Hoorn · Hoorn, Netherlands
    • NZ Respiratory & Sleep Institute · Auckland, New Zealand
    • Specjalistyczny Osrodek Alergologiczno-Internistyczny ALL-MED · Krakow, Poland
    • Ewa Pisarczyk-Bogacka Specjalistyczna Praktyka Lekarska · Wroclaw, Poland
    • ETG Lodz · Lódz, Poland
    • Centrum Medyczne Bydgoszcz- PRATIA - PPDS · Bydgoszcz, Poland
    • Jeonbuk National University Hospital · Jeonju, South Korea
    Show 7 removed
    • National Jewish Health · Denver, United States
    • Spartanburg Medical Center · Spartanburg, United States
    • Centrum Medyczne ALL-MED · Krakow, Poland
    • ETG Lodz · Lódz, Poland
    • ETG Siedlce · Siedlce, Poland
    • Dobrostan Gabinety Lekarskie · Wroclaw, Poland
    • Chonbuk National University Hospital · Jeonju, South Korea
    Primary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionAnnualized Rate of Moderate and Severe COPD Exacerbations Over the 52-Week Treatment Period: how it is measured was reworded
    Secondary outcomes 5 edited, 6 added, 1 removed, 1 description edited
    What changed in the outcomes
    • EditedAbsolute Change fromFrom Baseline in Health-Relatedrelated Quality -of Life-life (HRQoL) at Week 52, as Assessed Through the St. George's Respiratory Questionnaire-COPD (SGRQ-C) Total ScoreTime frame: Baseline to Week 52 → At Week 52
    • EditedAbsolute Change fromFrom Baseline in Post-Bronchodilatorbronchodilator Forced Expiratory Volume in 1 Second (FEV1) (litersLiters) at Week 52Time frame: Baseline to Week 52 → At Week 52
    • EditedAbsolute Change fromFrom Baseline in Evaluating Respiratory Symptoms in COPD (E-RS:COPD) Total Score at Week 52Time frame: Baseline to Week 52 → At Week 52
    • EditedAnnualized Rate of Moderate and Severe COPD Exacerbations Over the 52-Week Treatment Period in Participants With Low Baseline Blood Eosinophil Level (< 300 Cells/uL)Time frame: Baseline up to Week 52 → Baseline to Week 52
    • EditedAbsolute Change fromFrom Baseline in Five-Repetitionrepetition Sit-to-Standstand (5STS) timeTime (secondsSeconds) at Week 52Time frame: Baseline to Week 52 → At Week 52
    • AddedPercentage of Participants With Improvement in HRQoL at Week 52, as Assessed Through SGRQ-C Total ScoreTime frame: At Week 52
    • AddedAnnualized Rate of Severe COPD Exacerbations Over the 52-week Treatment PeriodTime frame: Baseline up to Week 52
    • AddedNumber of Participants With Adverse Events (AEs)Time frame: Up to 98.1 weeks
    • AddedMain Study: Serum Concentrations of Astegolimab at Specified TimepointsTime frame: Period 1: Pre-dose on Day 1 of Week 1 and at Weeks 4, 12, 24, 36, 52 and 62 (SFU); Period 2: Pre-dose at Weeks 52, 64, 76, 88, and 98 (SFU)
    • AddedIntensive PK Sampling Substudy: Serum Concentrations of Astegolimab at Specified TimepointsTime frame: Period 1: Pre-dose on Day 1 of Week 1 and at Weeks 4, 12, 24, 36, 48, 52, and 62 (SFU), Post-dose on Days 3, 7, and 10 of Week 1, Day 7 of Week 48, Day 28 post-dose from Week 52; Period 2: Pre-dose at Weeks 52, 64, 76, 88, and 98 (SFU)
    • AddedNumber of Participants With Anti-drug Antibodies (ADAs) to AstegolimabTime frame: Up to 98.1 weeks
    • RemovedProportion of SGRQ-C Responders at Week 52Time frame: Baseline to Week 52
    • DescriptionTime to First Moderate or Severe COPD Exacerbation During the 52-Week Treatment Period: how it is measured was reworded
    + 3 other changes: verification date, registry dates and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05037929
Lead sponsor
Genentech, Inc.
Responsible party
Sponsor
First posted
Sep 8, 2021
Start date
Oct 5, 2021
Primary completion
Feb 24, 2025
Completion
Jul 7, 2025
Results posted
Oct 16, 2026
Last update
Oct 16, 2026

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Astegolimab

Start the discussion